The top 5 trends in biotech – #3: High valuations for attractive biotechs are a durable symptom of a thriving financing arena

It’s been interesting watching the various big biopharma players executing their M&A strategies for 2017. Some, like the acquisitive Pfizer, have drawn back in hopes that tax reform allows them to repatriate billions in overseas accounts. Quite a few — take Roche for example — hate the valuations on the biotech drugs they are interested in. Gilead, meanwhile, patiently waited out repeated demands from analysts that they do something now(!) and then pounced on Kite, happily paying a massive premium for the biotech in order to become — overnight — a leader in CAR-T.

To me, it’s the aggressive Gileads of the world — going their own way, undaunted and undistracted by issues beyond their control — that have the right strategy. And while clearly risky, the fundamental drivers behind high valuations in biotech will keep the pressure on more M&A at some jaw-dropping sums.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->